News
Eli Lilly says new GLP-1 weight loss pill could reach market in 2026
Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill for FDA approval by the end of the year. The pill does not produce the same amount of weight loss as injections,
Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...
Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Novo, valued at $650 billion in June last year, has shed over two-thirds of its value since. Its latest market cap is around ...
Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...
The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback